This is a Class I recall where 56 serious injuries have been reported. If you use one of Dexcom's continuous glucose monitoring systems, here's what you need to know. Taylor Leamey wrote about all ...

Bullish option flow detected in DexCom (DXCM) with 1,753 calls trading, 1.1x expected, and implied vol increasing almost 2 points to 45.27%.

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose ...

Diabetes is a disease in which there is too much sugar in a person's blood. Type 2 diabetes is most common and is caused by factors such as obesity or lack of exercise. Rising obesity rates are a big ...

Oura and Dexcom are partnering on metabolic health — and they mean big business. Dexcom has invested $75 million into Oura to make the deal happen, valuing Oura at $5 billion. That works out to just a ...

DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...

DexCom announced that Chairman and CEO Kevin R. Sayer has taken a temporary medical leave as of September 14, 2025, with President and COO Jacob S. Leach appointed interim CEO and Mark Foletta as ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

We think that DexCom stock (NASDAQ NDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s DXCM better prospects and comparatively lower valuation. DXCM stock trades ...